Repligen Files IND for Neurodegenerative Disease Treatment

Repligen has filed an investigational new drug application with the US FDA for a Phase I study of its selective HDAC3 inhibitor, RG2833. While Repligen’s initial drug development focus will be Friedreich’s ataxia, RG2833 may have a broader therapeutic use for the treatment of ALS and other neurodegenerative diseases.

Click here to read more.

Share this: